로딩 중…
지수 로딩 중…
BioInfra Co., Ltd.
199730· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩3,015+4.51%
2026-06-19
Price Chart
BioInfra Co., Ltd.-45.48%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 14.67B KRW |
| Revenue | 23.21B KRW |
| Net Income | -4.34B KRW |
| Total Assets | 34.48B KRW |
| Net Assets | 12.54B KRW |
| Employees | 132 |
| Value | |
| P/B | 1.17x |
| P/S | 0.63x |
| FCF Yield | -19.25% |
| Profitability | |
| ROE | -34.62% |
| ROA | -12.59% |
| Op. Margin | -4.76% |
| Revenue Growth | 1.08% |
| Financial Health | |
| Debt Ratio | 274.97% |
| Total Debt | 12.70B KRW |
| FCF | -2.82B KRW |
| Cash | 2.96B KRW |
| Current Ratio | 0.59x |
| Dividend | |
| Div. Yield | 10.40% |
| Div. Growth | -25.00% |
| Performance | |
| 1Y Return | -45.48% |
| 1M Return | -15.78% |
| From 52W High | -52.37% |
| 1Y MDD | -50.85% |
| Trading | |
| Volume | 26,760 shares |
| Foreign Own. | 1.87% |
| Per Share | |
| EPS | -2,033 KRW |
| BPS | 2,578 KRW |
Company Info
The company was established in 2007 as a Contract Research Organization (CRO) and listed on the KOSDAQ market in 2023 as a small and medium-sized venture company. Its main businesses include bioequivalence tests for generic medicines, Phase 1 clinical trials for incrementally modified drugs, clinical trials for regulatory approval, immunoanalysis, and pharmaceutical quality testing. The company holds six domestic and international patents in analysis technology and automation, including for tube opening/closing devices and dispensing systems in Korea, the U.S., and Japan. Bioinfra, founded in 2007, is headquartered in Gyeonggi-do, Yongin-si.